Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 7 Associations of trans-lycopene with OA based on dataset A (trans-lycopene ≥ 19.49 µg/dl and age ≤ 65 years)

From: Relationship between serum carotenoids and osteoarthritis or degenerative arthritis: A cross-sectional study using the National Health and Nutrition Examination Survey

 

Crude model

Model 1

Model 2

Model 3

 

Model 4

 

OR 95%CI

P

OR 95%CI

P

OR 95%CI

P

OR 95%CI

P

OR 95%CI

P

Per-SD Trans Lycopene (ug/dL) increase

0.94 (0.83–1.06)

0.298

0.95 (0.84–1.09)

0.480

0.94 (0.83–1.06)

0.303

0.94 (0.83–1.06)

0.312

0.96 (0.85–1.08)

0.456

Quintile of Trans Lycopene (Q1-Q5)

 Q1 (2.97—3.13 ug/dL)

reference

reference

reference

reference

reference

 Q2 (3.13—3.27 ug/dL)

1.22 (0.80–1.88)

0.351

1.19 (0.76–1.87)

0.433

1.13 (0.72–1.77)

0.592

1.11 (0.70–1.75)

0.644

1.15 (0.74–1.79)

0.518

 Q3 (3.27—3.42 ug/dL)

0.93 (0.68–1.27)

0.640

0.92 (0.67–1.27)

0.598

0.84 (0.61–1.14)

0.256

0.83 (0.60–1.15)

0.263

0.87 (0.63–1.20)

0.379

 Q4 (3.42—3.61 ug/dL)

1.15 (0.77–1.71)

0.496

1.15 (0.76–1.75)

0.490

1.05 (0.70–1.56)

0.816

1.04 (0.69–1.55)

0.858

1.08 (0.72–1.62)

0.705

 Q5 (3.61—4.39 ug/dL)

0.86 (0.60–1.24)

0.410

0.90 (0.62–1.30)

0.562

0.85 (0.59–1.22)

0.377

0.85 (0.59–1.22)

0.367

0.90 (0.63–1.29)

0.571

P for trend

0.296

0.485

0.298

0.302

0.477

  1. The crude model was not adjusted. Model 1 was adjusted for sex, race, education level and family income. Model 2 was built upon Model 1, incorporating indicators closely related to OA, such as a history of osteoporosis, serum calcium and phosphorus levels, as well as histories of hypertension and diabetes. Model 3, an extension of Model 2, was further adjusted for lifestyle factors, including drinking or smoking habits and regular engagement in moderate or vigorous physical activity. The fully adjusted model (Model 4) was derived from Model 3, with additional adjustments for NHANES cycle